Azithromycin: can its benefit be ruled out in mild COVID-19? | Lancet Respir Med;9(10): 1079-1081, 2021 10. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

WHO COVID-19 Research Database

News/Update/Help

Advanced Search

The WHO Covid-19 Research Database is a resource created in response to the Public Health Emergency of International Concern (PHEIC). Its content remains searchable and spans the time period March 2020 to June 2023. Since June 2023, manual updates to the database have been discontinued.

Azithromycin: can its benefit be ruled out in mild COVID-19?

Rodríguez-Molinero, Alejandro.

Rodríguez-Molinero A; Àrea de Recerca, Consorci Sanitari de l'Alt Penedès i Garraf, Vilafranca del Penedès, Barcelona 08720, Spain. Electronic address: arodriguez@csapg.cat.

Lancet Respir Med ; 9(10): 1079-1081, 2021 10.

Article in English | MEDLINE | ID: covidwho-1442649

Subject(s)

Azithromycin; COVID-19 Drug Treatment; Humans; SARS-CoV-2

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Azithromycin / COVID-19 Drug Treatment Limits: Humans Language: English Journal: Lancet Respir Med Year: 2021 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Azithromycin / COVID-19 Drug Treatment Limits: Humans Language: English Journal: Lancet Respir Med Year: 2021 Document Type: Article